Verastem Oncology Reports Results of Copiktra (Duvelisib) in P-III DUO Study in Patients with R/R CLL/SLL
Shots:
- The P-III DUO study involves assessing of Copiktra (Duvelisib) vs ofatumumab in 319 patients with r/r CLL (n=312)/SLL (n=7) after at least two prior therapies in ratio 1:1
- The P-III study results: ORR (78% vs 39%); PFS (16.4mos. vs 9.1 mos.); presented at 23rd Annual International Congress on Hematologic Malignancies
- Copiktra(25mg- q2d) is an oral inhibitor of PI3Ki (phosphoinositide 3-kinase)- first approved dual inhibitor of PI3K-delta and PI3K-gamma. On 24 Sept-2018- Copiktra received FDA’s approval for r/r CLL/SLL and accelerated approval for r/r follicular lymphoma (FL)
Ref: Verastem Oncology | Image: Verastem Oncology
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com